NasdaqGS - Delayed Quote USD

Axonics, Inc. (AXNX)

66.84 -0.11 (-0.16%)
At close: April 22 at 4:00 PM EDT
66.83 -0.01 (-0.01%)
Pre-Market: 7:44 AM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Raymond W. Cohen CEO & Director 1.71M -- 1959
Mr. Rinda K. Sama Chief Operating Officer 902.83k 1.78M 1979
Dr. John Woock Ph.D. Executive VP, Chief Marketing & Strategy Officer 902.83k 1.06M 1983
Mr. Alfred J. Ford Jr. Chief Commercial Officer 902.96k -- 1971
Ms. Kari Keese Chief Financial Officer -- -- --
Mr. Guangqiang Jiang Ph.D. Chief Technology Officer -- -- 1974
Mr. Neil Bhalodkar Vice President of Investor Relations -- -- --
Mr. Aaron Pettit General Counsel & Chief Compliance Officer -- -- --
Mr. Michael V. Williamson Esq., J.D. Senior VP, General & IP Counsel -- -- 1972
Dr. Karen L. Noblett M.A.S., M.D. Chief Medical Officer 651.4k 897.47k 1963

Axonics, Inc.

26 Technology Drive
Irvine, CA 92618
United States
949 396 6322 https://www.axonics.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
797

Description

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Corporate Governance

Axonics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 5. The pillar scores are Audit: 10; Board: 2; Shareholder Rights: 4; Compensation: 2.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Apr 29, 2024 - May 03, 2024
Axonics, Inc. Earnings Call

Related Tickers

LIVN LivaNova PLC
54.01
+3.21%
 
KIDS OrthoPediatrics Corp.
30.20
-0.36%
 
FNA Paragon 28, Inc.
9.79
-0.10%
 
IRTC iRhythm Technologies, Inc.
113.62
+1.36%
 
ATEC Alphatec Holdings, Inc.
12.79
+1.99%
 
IDYLF Imaging Dynamics Company Ltd.
0.0300
0.00%
 
CNMD CONMED Corporation
72.61
-0.04%
 
CVRX CVRx, Inc.
14.69
-1.41%
 
ABL.DE Abbott Laboratories
100.00
-0.68%
 
ITGR Integer Holdings Corporation
116.65
+0.03%